SpyGlass Pharma Secures CPT Code for Glaucoma-Cataract Combo Therapy

Event summary

  • SpyGlass Pharma received a new Category III CPT code for its BIM-IOL System, enabling reimbursement for glaucoma treatment during cataract surgery.
  • The code (+X659T) covers attachment and insertion of the intraocular drug delivery implant.
  • Phase 3 trials for the BIM-IOL System are on track to complete enrollment in 2027.
  • The BIM-IOL System delivers bimatoprost for up to three years to reduce intraocular pressure in glaucoma patients.

The big picture

SpyGlass Pharma's CPT code approval marks a strategic milestone in integrating glaucoma treatment with routine cataract surgery, addressing a significant unmet need in ophthalmology. The approval could set a precedent for reimbursement models for combination therapies in chronic eye conditions, potentially expanding the company's market reach. The success of this model will depend on FDA approval and surgeon adoption rates.

What we're watching

Regulatory Approval
Whether the FDA approval process for the BIM-IOL System will align with the company's timeline for commercialization.
Market Adoption
The pace at which cataract surgeons adopt the BIM-IOL System following CPT code approval and potential FDA clearance.
Reimbursement Impact
How the new CPT code will influence reimbursement rates and patient access to the BIM-IOL System.